Ofatumumab versus Teriflunomide in Multiple Sclerosis.
| Author | |
|---|---|
| Abstract | :
Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known. |
| Year of Publication | :
2020
|
| Journal | :
The New England journal of medicine
|
| Volume | :
383
|
| Issue | :
6
|
| Number of Pages | :
546-557
|
| Date Published | :
2020
|
| ISSN Number | :
0028-4793
|
| URL | :
https://www.nejm.org/doi/10.1056/NEJMoa1917246?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
|
| DOI | :
10.1056/NEJMoa1917246
|
| Short Title | :
N Engl J Med
|
| Download citation |